1. Home
  2. BCG vs ALLR Comparison

BCG vs ALLR Comparison

Compare BCG & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.48

Market Cap

26.7M

Sector

N/A

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
ALLR
Founded
2016
2004
Country
United States
United States
Employees
150
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.7M
25.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BCG
ALLR
Price
$1.48
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
27.4K
220.0K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$0.77
52 Week High
$3.44
$2.35

Technical Indicators

Market Signals
Indicator
BCG
ALLR
Relative Strength Index (RSI) 37.06 46.37
Support Level $1.52 $1.29
Resistance Level $2.49 $1.80
Average True Range (ATR) 0.09 0.14
MACD 0.01 -0.04
Stochastic Oscillator 20.01 35.11

Price Performance

Historical Comparison
BCG
ALLR

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: